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Abstract: Dengue nonstructural protein 1 (NS1) is a multi-functional glycoprotein with essential
functions both in viral replication and modulation of host innate immune responses. NS1 has been
established as a good surrogate marker for infection. In the present study, we generated four anti-NS1
monoclonal antibodies against recombinant NS1 protein from dengue virus serotype 2 (DENV2),
which were used to map three NS1 epitopes. The sequence 193AVHADMGYWIESALNDT209 was
recognized by monoclonal antibodies 2H5 and 4H1BC, which also cross-reacted with Zika virus
(ZIKV) protein. On the other hand, the sequence 25VHTWTEQYKFQPES38 was recognized by mAb
4F6 that did not cross react with ZIKV. Lastly, a previously unidentified DENV2 NS1-specific epitope,
represented by the sequence 127ELHNQTFLIDGPETAEC143, is described in the present study after
reaction with mAb 4H2, which also did not cross react with ZIKV. The selection and characterization
of the epitope, specificity of anti-NS1 mAbs, may contribute to the development of diagnostic tools
able to differentiate DENV and ZIKV infections.
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1. Introduction
Dengue fever is an important mosquito-borne and the most prevalent and costly arbovirus
affecting humans, caused by one of the four serotypes of dengue virus (DENV 1–4) [1]. In the last
decade, a large number of dengue epidemics have occurred, which resulted in enormous economic
and human loss in parts of Asia and South America [2,3]. Considering Brazil only, more than three
million cases of confirmed dengue infections occurred between 2015 and 2017, with 70 cases per
100,000 inhabitants [4].
The DENV genome is composed of a single positive-sense RNA that encodes a single viral
polyprotein that is further processed by viral and host proteases into three structural proteins
(C, prM/M, and E) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5).
NS1 is the first nonstructural protein to be translated and is essential to virus replication [5]. It is
a conserved N-linked glycoprotein with a variable molecular mass of 46–55 kDa, which depends
on its glycosylation status [6]. The NS1 protein can be found as a dimer associated with vesicular
compartments within the cell, where it plays an important role as an essential cofactor in the virus
replication process [7]. Alternatively, NS1 can be secreted into the extracellular space as a hexameric
lipoprotein particle [8] that interacts with several plasma proteins [9,10].
The recent introduction of the Zika virus (ZIKV) to the American continent represented a regional
and worldwide public health challenge [11]. The close evolutionary relationship between DENV and
ZIKV is reflected by the high sequence conservation of both structural and non-structural proteins [12].
In this aspect, the identification of monoclonal antibodies (mAbs) able to react specifically with DENV
or cross-react with ZIKV proteins is a relevant feature for the validation of the diagnostic tools based
on the NS1 protein.
In pioneering work by Falconar et al. [8], the immunogenic regions of DENV2 NS1 employing
mAbs were extensively studied. Recently, certain studies have been using new methods to predict the
binding epitopes of proteins to specific antibodies [13,14]. This approach was also applied to identify
binding epitopes of DENV NS1 protein serotypes [15–17]. Also, the crystal structure of the DENV2
NS1 protein (PDB code: 4O6B) has been solved in both dimeric and hexameric configurations [6],
which provides a useful guide for the selection of potential epitopes for therapy and vaccine strategies.
In the present study, recombinant DENV2 NS1 was used to immunize mice and generate murine
mAbs. Four mAbs were isolated, purified, characterized and tested for reactivity with native NS1
produced by all DENV serotypes in Vero-infected cells and also for cross-reactivity with ZIKV NS1.
2. Results
2.1. Isolation and Characterization of NS1-Specific DENV mAbs
Fusion of popliteal lymph node cells, from mice immunized with DENV2 rNS1, with a
non-Ig-secreting or synthesizing line derived from a cell line created by fusing a BALB/c mouse spleen
cell and the mouse myeloma P3X63Ag8 (SP2/O-Ag14) mouse myeloma cells, generated 25 secretory
hybridomas. Among them, four hybridomas were selected by enzyme-linked immunosorbent assay
(ELISA) and sub cloned by limiting dilution and named as 4F6, 4H2, 4H1BC, and 2H5. The clones
were expanded, supernatants collected and mAbs purified for further characterization. Accordingly,
mAbs 4F6 and 4H2 were characterized as IgG2a (immunoglobulin G), and 2H5 and 4H1BC as IgG1.
The affinity constants were similar (10−8 M) as well as their reactivity with and limits of detection of
NS1 (Table 1).
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Table 1. Characteristics of the monoclonal antibodies (mAbs) against dengue virus (DENV) nonstructural protein 1 (NS1).
Name 4F6 4H2 2H5 4H1BC
IgG Subtype a IgG2a IgG2a IgG1 IgG1
DENV2 NS1 reactivity b Yes Yes Yes Yes
Dissociation Constant (KD) c 1.1 × 10−8 M 6.2 × 10−8 M 7.3 × 10−8 M 8.4 × 10−8 M
Detection limit d 16 ng/mL 32 ng/mL 32 ng/mL 32 ng/mL
Epitope sequence e 25VHTWTEQYKFQPES38 127ELHNQTFLIDGPETAEC143 193AVHADMGYWIESALNDT209 193AVHADMGYWIESALNDT209
DENV (1–4) reactivity f No Yes No No
ZIKV reactivity g No No Yes Yes
a The Ig isotype and IgG subtypes were performed by enzyme-linked immunosorbent assay (ELISA) using anti-IgA, anti-IgM, anti-IgG1, anti-IgG2a, anti-IgG2b and anti-IgG3 coated
onto microplates; b The Dengue virus serotype 2 (DENV2) NS1 reactivity was evaluated by indirect ELISA and immunoblotting using rNS1; c Dissociation constant was performed by
ELISA [18]; d Detection limit was evaluated by ELISA using different concentrations of rNS1; e The conservancy of DENV2 NS1 epitopes recognized by specific mAbs in a peptide array
was analyzed among the four serotypes of DENV, using three samples of NS1 amino acid sequences as representative of each DENV serotype; f,g DENV (1–4) and Zika virus (ZIKV)
reactivity was evaluated by immunofluorescence in Vero cells infected with the specific virus strains.
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The recognition pattern of the four NS1 mAbs was evaluated by ELISA using either intact or
heat-denaturated rNS1. All NS1 mAbs recognized the intact rNS1 protein, and although mAb 4F6
reacted similarly with the intact and the heated-treated rNS1 (Figure 1A), the other three mAbs
(4H2, 2H5 and 4H1BC) reacted more efficiently with the intact protein (Figure 1B–D, respectively),
which indicated that the recognized epitopes were, at least, partially represented by conformational
structures. All four MAbs also recognized rNS1 in an immunoblot assay (Figure S1).
Figure 1. Characterization of nonstructural protein 1-specific (NS1) monoclonal antibodies (mAbs)
reactivity by enzyme-linked immunosorbent assay (ELISA). Reactivity of mAbs to heated-treated or
intact rNS1, as solid phase-bound antigens. The mAbs 4F6 (A), 4H2 (B), 2H5 (C) and 4H1BC (D) were
serially diluted (log2) from an initial concentration of 2.5 µg/mL. Each well was adsorbed with 400 ng
of rNS1. Heat denaturation was performed at 100 ◦C for 10 min. Statistical analyses were performed
by two-way variance analysis followed by Bonferroni’s post-test. (*** p < 0.01; ** p < 0.1; * p < 0.5).
2.2. Detection of Native DENV2 NS1 and Epitope Mapping
After selection, mAbs were tested by immunofluorescence assays using fixed DENV2-infected
Vero cells. All four mAbs recognized the native viral NS1 expressed in infected cells, as shown in
Figure 2. To localize the specific mAbs binding sites/epitopes, peptide mapping array experiments
were performed (Figure S2). The results showed that mAb 4F6 reacted with the peptide corresponding
to the sequence 25VHTWTEQYKFQPES38 of NS1 (Table 1), which is located in an external loop of the
protein 3D structure (Figure 3). The 4H2 mAb recognized the peptide corresponding to the sequence
127ELHNQTFLIDGPETAEC143 of NS1 (Table 1), which is located in beta-sheets in an external region of
the protein 3D structure (Figure 4). The other two mAbs (2H5 and 4H1BC) showed the same binding
specificity and recognized the peptide 193AVHADMGYWIESALNDT209 (Table 1). This sequence was
also located in a beta-sheet structure, located in an internal region of the protein (Figure 5). The analysis
of epitope conservancy in several strains of DENV serotypes as well as Zika strains is detailed in
Table S1.
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Figure  2.  Reactivity  of NS1‐specific mAbs  to  dengue‐serotype  2‐infected  Vero  cells.  Cells were 
infected with a multiplicity of infection (MOI) of 0.5, fixed, permeabilized and treated with each of 
the tested mAbs 48 h post infection. Then, cells were labeled with Alexa fluor® conjugated goat‐anti 
mouse IgG. The negative controls: Mock‐infected cells treated with a pool of mAbs anti‐NS1 (A) and 
DENV2‐infected cells labeled only with secondary antibody (B); Tested mAbs: (C) 4F6; (D) 4H2; (E) 
2H5 and (F) 4H1BC. Magnification of 200×. 
Figure 2. Reactivity of NS1-specific mAbs to dengue-serotype 2-infected Vero cells. Cells were
infected with a multiplicity of infection (MOI) of 0.5, fixed, permeabilized and treated with each of
the tested mAbs 48 h post infection. Then, cells were labeled with Alexa fluor® conjugated goat-anti
mouse IgG. The negative controls: Mock-infected cells treated with a pool of mAbs anti-NS1 (A) and
DENV2-infected cells labeled only with secondary antibody (B); Tested mAbs: (C) 4F6; (D) 4H2; (E) 2H5
and (F) 4H1BC. Magnification of 200×.
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Figure 3. Three‐dimensional structural model of a NS1 dimer and regions corresponding to epitopes 
recognized  by  4F6 mAb.  The NS1  3D model was  generated  by  the  program  Python Molecular 
(PyMOL) in green. The sequence 25VHTWTEQYKFQPES38 is highlighted in yellow. 
 
Figure 4. Three‐dimensional structural model of a NS1 dimer and regions corresponding to epitopes 
recognized by 4H2 mAb. The NS1 3D model was generated by the program PyMOL in green. The 
sequence 127ELHNQTFLIDGPETAEC143 is highlighted in red and white. In the detail the red structure 
represents the novel nine‐amino acid sequence described herein. 
i r . r e-di ensional structural model of a NS1 dimer and regions corresponding to epitopes
recog ize by 4F6 mAb. The NS1 3D model was generated by the program Python Molecular (PyMOL)
in green. The sequence 25VHTWTEQYKFQPES38 is highlighted in yellow.
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Figure 4. Three-dimensional structural model of a NS1 dimer and regions corresponding to epitopes
recognized by 4H2 mAb. The NS1 3D model was generated by the program PyMOL in green.
The sequence 127ELHNQTFLIDGPETAEC143 is highlighted in red and white. In the detail the red
structure represents the novel nine-amino acid sequence described herein.
Antibodies 2017, 6, 14 7 of 13
Antibodies 2017, 6, x FOR PEER REVIEW    4 of 13 
 
 
Figure 5. Three‐dimensional structural model of a NS1 dimer and regions corresponding to epitopes 
recognized by 2H5 and 4H1BC mAbs. The NS1 3D model was generated by the program PyMOL in 
green. The sequence 193AVHADMGYWIESALNDT209 is highlighted in blue. 
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the selected mAbs were  tested for recognition of native ZIKV NS1 by  immunofluorescence assay, 
using fixed ZIKV‐infected Vero cells. In Figure 6, two mAbs are observed to cross‐react with native 
ZIKV‐NS1 in this test (2H5 and 4H1BC) (Figure 6C,D, Table 1). The other two mAbs (4F6 and 4H2) 
were specific for DENV NS1 (Figure 6A,B, Table 1). We also tested in vitro the reactivity of 4F6 and 
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Figure 6. Reactivity of NS1‐specific mAbs to zika virus‐infected Vero cells. Cells were infected with a 
MOI of 0.05. 72 h post infection, cells were fixed, permeabilized and treated with each of the tested 
mAbs. Then, cells were labeled with FITC‐conjugated goat‐anti mouse IgG. Tested mAbs: (A) 4F6, (B) 
4H2, (C) 2H5 and (D) 4H1BC. Magnification of 200×. 
Figure 5. Three-dimensional structural model of a NS1 dimer and regions corresponding to epitopes
recognized by 2H5 and 4H1BC mAbs. The NS1 3D model was generated by the program PyMOL in
green. The sequence 193AVHADMGYWIESALNDT209 is highlighted in blue.
2.3. Analyses of mAbs’ Cross-Reactivity with Different DENV Serotype and ZIKV
Sinc NS1 share a high homology with amino cid sequences found among different flavivirus,
the selected mAbs wer sted for recogn tion of native ZIKV NS1 by immunofluoresce ce assay,
using fixed ZIKV-infected Vero cells. In Figure 6, two mAbs are observed t cros -react with native
ZIKV-NS1 in this test (2H5 and 4H1BC) (Figure 6C,D, Table 1). The other two mAbs (4F6 and 4H2)
were specific for DENV NS1 (Figure 6A,B, Table 1). We also tested in vitro the reactivity of 4F6 and
4H2 mAbs with DENV serotypes, other than DENV2, and only the 4H2 mAb reacted with all four
DENV serotypes (Figure 7, Table 1).
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Figure 6. Reactivity of NS1-sp cific mAbs to zika virus-infected Vero cells. Cells were infected with a
MOI of 0.05. 72 h post infection, cells were fixe , er eabilized and treated with each of the tested
mAbs. Then, cells wer labeled I C-conjugated go t-anti mouse IgG. Tested m bs: (A) 4F6;
(B) 4 2; and (D) 4H1BC. Magnificati n of 200×.
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(A) Mock infected cells treated with a p ol of mAbs anti-NS1 and (B) DENV-infect d cells labeled
only with second ry antibody; Tested DENV serotypes: (C) DENV1; (D) DENV3 and ( ) .
agnification of 200×.
3. iscussion
The E S1 has been used as a target antigen against dengue infecti eit er f r vacci ,
antiviral drug design or diagnostic ethods. Indeed, this protein is secreted by infected cel s during
the acute phase and circulates in the blood at high concentrations [19]. evertheless, the S1 shares
parts of its amino acid sequence among flavivirus. I t rese t st , we generated four mAbs
against DE V2 reco binant NS1 and analyzed their reactivity with the dimeric-NS1 form. The
Abs were also reactive with the native NS1 produced in infected c lls but showed differ nt features.
The epitope s quences recognized by different mAbs hav been recently described a d been onsi ered
th strateg c poin for understanding these interactions [15–17].
The 2H5 and 4H1BC showed a similar recog ition pattern and share the same
epitope binding, 193AVHADMGYWIESALNDT209. This epitope has been reported as one of the
i uno o i t cel epito es in E 2 S1 [20]. This seque ce as describe in silico and is
buried in a beta-sheet structure [15,17]. The recogniti of the heat-denat re r S1 as lo er for
these bs hen co pared with the non-denatured rNS1, suggesting that these mAbs recognize
ainly a conformational epitope. Indee , by immunofluorescence, both 2H5 and 4H1BC mAbs reacted
with dengue virus serotype 2 infected Vero ells. However, they cross-reacted with native ZIKV NS1
in Vero infected c lls. The in silico analyses of the similarity of is peptide sequence b tween different
flaviviruses showed that this pitope is highly conserved in t ese virus but not Yellow fe er, Japanese
encephalitis and West Nile viruses (Table S2).
The Ab 4F6 recognizes the DENV2 complex-conserved LD2 epitope 25V T TEQYKFQPES38,
located on the surface of NS1 fusion loop [8,15,17]. previous study sho e a b that binds in
this motif is able to recognize th purified NS1 hexamer from all f ur DENV serotypes [21]. However,
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4F6 mAb was able to detect only DENV2 native monomeric NS1 by immunofluorescence but no other
serotypes. The divergent results may be accounted to methodological issues, since immunofluorescence
is less sensitive and aims to detect infected cells expressing mainly monomeric intracellular NS1,
while the purified hexamers were used in an ELISA-based detection system. Hence, this epitope may
be exposed depending on the NS1 oligomeric level and the DENV serotype.
The fourth mAb obtained, 4H2, recognized the amino acid sequence 127ELHNQTFLIDGPET
AEC143. A preceding work described a shorter sequence, 125STESHNQTFL134 exposed in the same
loop of DENV2 NS1 [15]. Interestingly, the sequence herein described has nine additional amino acids
not previously reported as a B cell epitope and shifting the exposed region to a beta-sheet structure.
It recognizes the native protein assessed by immunofluorescence of the four DENV serotypes infected
Vero cells, but it did not cross-react with native ZIKV NS1 in Vero-infected cells.
Differentiation of DENV and ZIKV infections is a challenge for current serological tests,
particularly in areas where both viruses circulate and co-infection can occur. Thus, mAbs, like 4H2,
may be particularly useful for the development of an immunofluorescence based-assay that minimizes
the risks associated with false positive results among ZIKV-infected subjects.
4. Materials and Methods
4.1. Viral Strains and Viral Antigen
The obtention of purified DENV2 NS1 dimers was achieved after denaturation/refolding
steps of the protein expressed in E. coli followed by affinity chromatography, as previously
reported [22]. This recombinant protein was utilized as an antigen for monoclonal antibody
development and characterization. Four dengue serotypes and one Zika virus strain were used
for further characterization of the mAbs obtained: a dengue virus serotype 2 JHA1 strain [23,24],
a rDEN1∆30 vaccine strain obtained by ∆30 deletion in 3′UTR of DENV1 Western Pacific strain [25],
a rDEN3∆30/31-7164 vaccine strain obtained by ∆30 and ∆31 deletions in 3′ untranslated region (UTR)
of DENV3 Slemann/78 strain [26], a rDEN4∆30 vaccine strain obtained by ∆30 deletion in 3′ UTR
of DENV4 Dominica/81 strain [27], and a Brazilian Zika virus strain (ZIKVBR) (Evandro Chagas
Institute, Belem, PA, Brazil).
4.2. Dengue NS1 Monoclonal Antibody (mAb) Production
Four to six week-old female BALB/c mice were immunized via footpad route with 10 µg rNS1
adsorbed to 1 µg recombinant heat-labile toxin (rLT) [22] as adjuvant. The immunization protocols
consisted of three booster injections of the rNS1 and rLT in 0.01 M phosphate buffered saline (PBS),
pH 7.4 at 15 days intervals. The mouse with the highest antibody titer was boosted with 10 µg of
rNS1 three days prior to cell fusion. The popliteal lymph node cells were fused to SP2/O-Ag14
mouse myeloma cells (2:1) using polyethylene glycol 1500 (Sigma Aldrich, St Louis, MO, USA) [28],
with modifications [29]. The supernatant fluids were screened for specific antibodies by indirect ELISA
in which 100 µL of hybridoma supernatant was added to a 96-well MaxiSorp microplates (Nunc®,
Rochester, NY, USA) previously coated with 1 µg/mL of purified rNS1 to screen cultures for antibody
production. Antibody-secreting cells were expanded and cloned at limiting dilution [29]. This study
was carried out in accordance with the recommendations of Ethical Principles in Animal Research,
adopted by the Brazilian College of Animal Experimentation. The protocol was approved by the
Ethical Committee for Animal Research of Butantan Institute (995/12).
4.3. Dengue NS1 mAbs Characterization
Hybridoma supernatants were incubated with each of the anti-isotype (anti-IgG1, anti-IgG2a,
anti-IgG2b, anti-IgG3, anti-IgA and anti-IgM antibodies) previously coated at MaxiSorp microplates
followed by incubation with horseradish peroxidase-conjugated rabbit anti-mouse-IgG+A+M+ (1:1000)
(Zymed, San Francisco, CA, USA) [27]. The supernatants from selected clones were filtered (0.45 µm)
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and purified by protein G affinity chromatography (GE-Healthcare, Freiburg, Germany). MAb purity
was observed in a 12% polyacrylamide gel electrophoresis containing sodium dodecyl sulphate
(SDS-PAGE) staining with Coomassie blue R-250.
The detection limit was established using rNS1 concentrations from 1 to 512 ng coated on
microplates, followed incubation with 10 µg/mL of NS1 mAb and with goat anti-mouse
peroxidase-conjugated antibody (Invitrogen, Carlsbad, CA, USA) diluted 1:5000. The three-step
ELISA was employed to determine the dissociation constants (KD) of antigen-antibody interactions
under equilibrium conditions [28].
ELISA assay was also applied in order to observe the reactivity of mAb NS1 against intact and
denatured rNS1. For this, MaxiSorp microplates (Thermo Fischer Scientific, Waltham, MA, USA) were
coated with 4 µg/mL of Dengue virus serotype 2 (DENV2) rNS1 heat-treated (100 ◦C for 10 min)
or non-heated. The NS1 mAbs were serially diluted (log2) in an initial concentration of 2.5 µg/mL
followed by incubation with goat anti-IgG mouse conjugated with horseradish peroxidase (1:10,000).
The reactivity of NS1 mAb against intact and denatured rNS1 was also analyzed by
immunoblotting. Thus, 1 µg or 0.5 µg of rNS1 denatured (heat-treated for 10 min at 100 ◦C) or intact
(non-heated) were separated by electrophoresis in denaturing condition polyacrylamide gel containing
sodium dodecyl sulphate (SDS-PAGE) 15%. Nitrocellulose membranes (GE-Healthcare, Freiburg,
Germany) containing the transferred proteins were tested with NS1 mAbs at a final concentration
of 200 ng/mL. Thus, the membranes were incubated with goat anti-IgG mouse conjugated with
peroxidase (1:10,000). The reactive protein bands were identified by exposing membranes to a solution
of luminol-hydrogen peroxide according to the manufacturer’s instructions (Sigma Aldrich, St Louis,
MO, USA). Images were captured by Image Lab™ software (Bio-Rad, Hercules, CA, USA).
4.4. Epitope Characterization and Structure Analysis
Peptide mapping was performed using CelluSpot Peptide Array (Intavis, Heidelberg, Germany)
following the manufacturer’s recommendations. The slides were produced with dots containing
11 amino acids with overlapping of eight amino acids. Briefly, the slides were blocked, followed
by incubation with 30 µg/mL mAb. Next, the slides were incubated with anti-mouse horseradish
peroxidase conjugate (1:5000). After washing, diaminobenzidine and hydrogen peroxide were added
and the reaction was stopped by the addition of distilled water.
We employed PyMol program (DeLano Scientific LLC, San Carlos, CA, USA, 2009) to predict
the structure and the epitope of NS1. For the NS1 structure, we used the available PDB file from
Protein Data Bank (code: 4O6B) [6]. For the structure of monoclonal antibodies, we first performed the
prediction with Phyre [30].
4.5. NS1 Sequences Database Building
One database consisting of amino acid sequences of the NS1 protein in FASTA format was built.
Sequences were retrieved from the National Center for Biotechnology Information (NCBI) protein
database. Sequences from serotype 1 of DENV have the following accession numbers: ABG75766,
ABG75761 and AFN54943. Sequences from serotype 2 of DENV have the following accession numbers:
AIE17400, ABK51383 and AFZ40226. Sequences from serotype 3 of DENV have the following accession
numbers: ADM63678, AAT79552 and ALI16137. Sequences from serotype 4 of DENV have the
following accession numbers: AGI95993, ALB78116 and AFD53008. Sequences from ZIKV isolates
have the following accession numbers: AMR39836, AMD61710, ASK51714, ARB07991, AMD16557
and ARB07967.
4.6. Conservancy Analysis
The IEDB conservancy analysis was used to determine the conservancy of epitopes for monoclonal
antibodies 4F6, 4H2, 2H5 and 4H1BC. A sequence identity threshold of ≥20% was applied.
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4.7. NS1 mAbs Reactivity to Dengue Virus Serotypes and Zika Virus
Vero cells grown on six-well plates were infected with the viral strains at a MOI of 0.5 for 48 h for
DENV and at a MOI of 0.05 for 72 h for ZIKV. The cells were fixed with 1% formaldehyde for 10 min at
4 ◦C and then permeabilized with 0.5% saponin in PBS for DENV and with cold acetone at −20 ◦C
for ZIKV. The cells were then blocked with PBS containing 10% bovine fetal serum for 30 min. Both
cells were treated with mAbs diluted in permeabilization buffer at a concentration of 10 µg/mL for 1 h
at room temperature for DENV and 37 ◦C for 30 min for ZIKV. After three washing steps with PBS,
the cells were further treated with Alexa fluor488® (Thermo Fisher, Waltham, MA, USA) conjugated
goat anti-mouse IgG at room temperature for 1 h. After another washing period (five times) with
PBS, cells were examined using an EVOS digital inverted microscope. Mock infected and cell infected
marked with just secondary antibody was the negative control. Also, Vero cells infected with ZIKVBR
were tested in order to determine the cross reactivity of the mAbs.
5. Conclusions
In the present study we generated four monoclonal antibodies against the nonstructural protein
1 (NS1) of dengue virus serotype 2. One of them (4H2 mAb) recognizes by immunofluorescence the
four-dengue virus serotype and did not cross react to zika virus. Thus, the selection and characterization
of the epitope, specificity of anti-NS1 mAbs, may contribute to the development of diagnostic tools
able to differentiate DENV and ZIKV infections.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4468/6/3/14/s1,
Figure S1: Characterization of NS1-specific mAbs reactivity by immunoblotting; Figure S2: Epitope mapping with
NS1-derived synthetic peptides; Table S1: Epitope analysis of conservancy in DENV serotypes. Table S2: Epitope
analysis of conservancy in different strains of DENV, ZIKV, YFV, JEV and WNV strains.
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